Clinic
Suffolk Primary Health, LLC
Suffolk Primary Health, LLC was paid $22.23M by Medicaid between Jan 2018 and Dec 2024, across 106 billing codes. Its largest line is G2023, Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source — 28% of everything it billed.
33Billing provider infoSUFFOLK PRIMARY HEALTH, LLC
RIVERHEAD, NY 11901
RIVERHEAD, NY 11901
33aNPI1174965727assigned 07/24/2013
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$22.23M
24GClaims643,427
24DCodes billed106
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in New York
Rank by total paid#5 of 118
Median peer was paid$372K
This provider vs. median60×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,204 | $54K | |
| 2019 | 2,232 | $145K | |
| 2020 | 3,200 | $206K | |
| 2021 | 5,897 | $210K | |
| 2022 | 152,389 | $4.52M | |
| 2023 | 424,709 | $13.59M | |
| 2024incomplete | 53,796 | $3.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 28% | 256,236 | 103,656 | $6.32M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 22% | 76,467 | 37,068 | $4.98M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 12% | 36,505 | 32,396 | $2.69M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 8.3% | 94,119 | 45,479 | $1.83M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.1% | 12,971 | 10,691 | $1.13M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.8% | 86,343 | 36,928 | $855K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.5% | 8,264 | 5,883 | $775K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.8% | 4,392 | 1,707 | $617K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 1,513 | 275 | $388K |
| 99401 | 1.2% | 6,966 | 4,442 | $269K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,748 | 292 | $255K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,009 | 449 | $203K |
94 more codes
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,797 | $202K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,518 | $191K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 991 | $176K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,905 | $166K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,296 | $140K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 3,210 | $132K |
| 99406 | <1% | 2,804 | $102K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 704 | $79K |
| 99442 | <1% | 760 | $78K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,455 | $68K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 735 | $57K |
| 99443 | <1% | 500 | $57K | |
| 99051 | <1% | 3,854 | $48K | |
| 99000 | <1% | 1,922 | $48K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 430 | $46K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 985 | $36K |
| 99441 | <1% | 320 | $36K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,215 | $33K |
| 90837 | Psychotherapy session, about an hour | <1% | 231 | $32K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 331 | $26K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 226 | $22K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 183 | $20K |
| 93922 | <1% | 171 | $19K | |
| 99385 | <1% | 107 | $13K | |
| 95923 | <1% | 121 | $12K | |
| 95921 | <1% | 180 | $10K | |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 141 | $8K |
| 99402 | <1% | 150 | $7K | |
| 93975 | <1% | 12 | $6K | |
| 93000 | <1% | 1,398 | $6K | |
| 99422 | <1% | 58 | $5K | |
| 80053 | Comprehensive metabolic panel | <1% | 264 | $4K |
| 93923 | <1% | 27 | $4K | |
| 95910 | <1% | 27 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 140 | $3K |
| 99403 | <1% | 47 | $3K | |
| 92227 | <1% | 25 | $2K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 12 | $2K |
| 80061 | Lipid panel | <1% | 204 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $2K |
| 95885 | <1% | 28 | $2K | |
| 99386 | <1% | 12 | $1K | |
| 96127 | <1% | 1,066 | $1K | |
| 90658 | <1% | 37 | $674.88 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 18 | $615.23 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 67 | $594.24 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 12 | $542.60 |
| 99454 | <1% | 48 | $489.96 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 18 | $464.03 |
| 99453 | <1% | 126 | $315.00 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 294 | $224.71 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 408 | $207.46 |
| 99421 | <1% | 17 | $140.85 | |
| 81001 | <1% | 686 | $133.47 | |
| 96160 | <1% | 39 | $83.40 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 40 | $54.25 |
| 99457 | <1% | 78 | $42.77 | |
| 99173 | <1% | 653 | $33.04 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 15 | $24.21 |
| 82607 | <1% | 109 | $21.35 | |
| 82746 | <1% | 102 | $16.44 | |
| 86376 | <1% | 62 | $13.33 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 107 | $6.38 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 44 | $4.67 |
| 83735 | <1% | 15 | $4.64 | |
| 84100 | <1% | 15 | $4.27 | |
| 86800 | <1% | 51 | $3.02 | |
| 84480 | <1% | 64 | $2.69 | |
| 84439 | <1% | 64 | $1.71 | |
| 83550 | <1% | 27 | $1.66 | |
| 84436 | <1% | 66 | $1.31 | |
| 84479 | <1% | 66 | $1.23 | |
| 83540 | <1% | 31 | $1.23 | |
| 3079F | 0% | 14 | $0.00 | |
| 3008F | 0% | 2,747 | $0.00 | |
| 1125F | 0% | 128 | $0.00 | |
| 1126F | 0% | 1,610 | $0.00 | |
| 87800 | 0% | 46 | $0.00 | |
| 76536 | 0% | 24 | $0.00 | |
| 99205 | Prolong outpt/office vis | 0% | 12 | $0.00 |
| 3044F | 0% | 61 | $0.00 | |
| 1170F | 0% | 16 | $0.00 | |
| 3049F | 0% | 15 | $0.00 | |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | 0% | 54 | $0.00 |
| 81000 | 0% | 18 | $0.00 | |
| 82728 | 0% | 15 | $0.00 | |
| 1159F | 0% | 2,784 | $0.00 | |
| 4004F | 0% | 349 | $0.00 | |
| 1160F | 0% | 3,051 | $0.00 | |
| 3050F | 0% | 83 | $0.00 | |
| 99072 | 0% | 1,674 | $0.00 | |
| 3725F | 0% | 27 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 120 | $0.00 |
| 99490 | Ccm add 20min | 0% | 92 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSWERDLOFF, MATISYAHU (CEO)